• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

NALBUPHINE Drug Record

  • Summary
  • Interactions
  • Claims
  • NALBUPHINE chembl:CHEMBL895 Approved

    Alternate Names:

    NUBAIN
    NALBUPHINE
    NUBAIN®
    NALBUFINA
    NALBUPHIN
    NALBUPHINUM
    N-CYCLOBUTYLMETHYL-4,5ALPHA-EPOXY-3,6ALPHA,14-MORPHINANTRIOL
    rxcui:7238
    drugbank:00844
    chembl:CHEMBL895
    chemidplus:20594-83-6
    pubchem.compound:5311304

    Drug Info:

    Year of Approval 1979
    Drug Class analgesics, opioid
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications analgesic
    (1 More Sources)

    Publications:

    Hoehe et al., 1993, Opiates increase plasma catecholamines in humans., Psychoneuroendocrinology
    Tao et al., 2006, Nalbuphine is effective in decreasing the rewarding effect induced by morphine in rats., Drug Alcohol Depend
    Picker, 1997, Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists., J. Pharmacol. Exp. Ther.
    Peng et al., 2007, Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors., J. Med. Chem.
    Meerpohl et al., 2008, [News from the cochrane library: mu opioid antagonists for opioid-induced bowel dysfunction]., Z Gastroenterol
    Smith et al., 2009, The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors., J. Pharmacol. Exp. Ther.
    Mello et al., 2005, Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men., Neuropsychopharmacology
    McNicol et al., 2008, Mu-opioid antagonists for opioid-induced bowel dysfunction., Cochrane Database Syst Rev
    Zernig et al., 1997, Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception., Psychopharmacology (Berl.)
    Kishioka et al., 2000, Diltiazem enhances the analgesic but not the respiratory depressant effects of morphine in rhesus monkeys., Eur. J. Pharmacol.
    Béguin C et al., 2012, Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues., Bioorg Med Chem Lett
    Chen et al., 2005, Dextromethorphan differentially affects opioid antinociception in rats., Br. J. Pharmacol.
    Gear et al., 1999, The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain., Pain
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    De Souza et al., 1988, Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic., J. Pharmacol. Exp. Ther.
    Chen et al., 1993, The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine., Life Sci.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
  • NALBUPHINE   OPRK1

    Interaction Score: 2.12

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name REN-213
    Novel drug target Established target
    Trial Name nalbuphine hydrochloride, PW-4142

    PMIDs:
    22204910 15655510 8388112 16517095 10534607 17407276 19403853 15602503 17016423 17139284


    Sources:
    DTC TdgClinicalTrial TEND TTD

  • NALBUPHINE   OPRD1

    Interaction Score: 1.26

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name nalbuphine hydrochloride, PW-4142
    Novel drug target Established target
    Trial Name REN-213

    PMIDs:
    2826773 8093631 11752352


    Sources:
    TdgClinicalTrial TEND

  • NALBUPHINE   OPRM1

    Interaction Score: 1.19

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name nalbuphine hydrochloride, PW-4142
    Novel drug target Established target
    Trial Name REN-213

    PMIDs:
    8388112 16517095 9399970 17407276 18810678 19403853 15602503 18425947 9084061 10844102


    Sources:
    TdgClinicalTrial TEND

  • NALBUPHINE   CYP1A2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • NALBUPHINE   CYP2D6

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • NALBUPHINE   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TEND: NALBUPHINE

    • Version: 01-August-2011

    Alternate Names:
    NALBUPHINE Primary Drug Name

    Drug Info:
    Drug Class analgesics, opioid
    Year of Approval 1979

    Publications:

  • TdgClinicalTrial: NALBUPHINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications analgesic
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: NALBUPHINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL895 ChEMBL Drug ID

    Drug Info:

    Publications:
    Béguin C et al., 2012, Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues., Bioorg Med Chem Lett
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • TTD: Nalbuphine

    • Version: 2020.06.01

    Alternate Names:
    D01KQA TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL895

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21